Crioestaminal's Owner Wants to Buy Rival Cord Blood Bank Bebévida, and Portugal's Competition Authority Opens an In-Depth Probe
The AdC says Stemlab's purchase of Cordvida and Stamcriovitae, which owns Bebévida, raises serious doubts about competition. The deal cannot close while a second phase of up to 90 working days runs.
Portugal's competition authority has opened an in-depth investigation into Stemlab's plan to buy Cordvida Portugal and Stamcriovitae, the companies behind the Bebévida cord blood bank. Stemlab trades as Crioestaminal. The AdC (Autoridade da Concorrência, the Competition Authority) said the deal raises "serious doubts" about whether it is compatible with effective competition.
The decision was taken by the AdC's board on 7 September and reported on Tuesday. It means the deal cannot go ahead until the authority has completed a longer second-phase investigation.
Who is involved
All the companies involved work in the same business. They collect, test, process and freeze stem cells, mainly from the umbilical cord blood and tissue taken at birth, and store them in their own facilities for families who pay to keep them. Stemlab uses the Crioestaminal brand. According to the notice the AdC published in May, Cordvida and Stamcriovitae do the same work indirectly: Stamcriovitae owns Bebévida (Bebévida, Ciências para a Vida, S.A.).
Stemlab notified the AdC on 4 May that it wanted sole control of Cordvida and, through it, Stamcriovitae. The case is registered as Ccent/2026/29.
What "serious doubts" means
Under the Lei da Concorrência (Competition Law, Law 19/2012), the AdC normally has 30 working days to review a notified deal. At the end of that first phase it can clear the deal, clear it with conditions, or open an in-depth investigation. It takes the last option when a deal "raises serious doubts" that it could create "significant impediments to effective competition in the national market or in a substantial part of it". That is the wording the AdC used here.
The second phase can last up to 90 working days, counted from the date the notification took effect, and can be extended by up to 20 working days at the buyer's request or with its agreement. The clock stops whenever the AdC asks the companies for more information, so the final decision date cannot be worked out from the published dates.
At the end of the investigation the AdC can clear the deal, clear it with commitments offered by the buyer, or block it. If it does not decide in time, the law treats the deal as cleared. A notified deal may not be completed before the authority clears it, whether expressly or tacitly.
The AdC has not said which markets concern it, and the reasoning behind its first-phase decision has not been published.
Why it matters to parents
Private cord blood storage is a service that families pay for around the time of a birth. If the deal goes through, Crioestaminal and Bebévida, two of the brands offered to expectant parents in Portugal, will have the same owner. That is the kind of loss of choice that merger control exists to test.
Until the AdC decides, the companies stay under separate ownership, because the law bars Stemlab from completing the purchase before clearance.
The AdC publishes each step in the case on its website, under the reference Ccent/2026/29.
